News Releases

Date	Title and Summary	View
Dec 06, 2019	Janssen Announces BCMA CAR-T Therapy JNJ-4528 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of Relapsed or Refractory Multiple Myeloma
Dec 05, 2019	Johnson & Johnson Names Hubert Joly, Executive Chairman of Best Buy and Mark A. Weinberger, Former EY Global Chairman and CEO to its Board of Directors NEW BRUNSWICK, N.J. , Dec. 5, 2019 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that Hubert Joly , Executive Chairman of Best Buy Co., Inc , and Mark A. Weinberger , Former EY Global Chairman and CEO, have been appointed to its Board of Directors.
Dec 03, 2019	ETHICON LAUNCHES VISTASEAL FIBRIN SEALANT (HUMAN) TO MANAGE BLEEDING DURING SURGERY
Dec 03, 2019	Johnson & Johnson Vision Introduces TECNIS Toric II 1-Piece IOL as New Monofocal Option for Cataract Patients with Astigmatism; Launching MultiCenter, Post-Market Clinical Trials Across U.S.
Dec 03, 2019	Company Investigation Confirms No Asbestos in Johnson’s Baby Powder
Nov 21, 2019	New Cervical Spine System from DePuy Synthes Advances Treatment Options for Patients with Complex Cervical Spine Disorders
Nov 19, 2019	Janssen Receives EU Marketing Authorisation for Darzalex®▼(daratumumab) in Combination with Lenalidomide and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible
Nov 12, 2019	Actelion Withdraws Regulatory Filings to Extend the Indication of OPSUMIT® (macitentan 10mg) in CTEPH
Nov 08, 2019	Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA Seeking Approval of IMBRUVICA® (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukemia
Nov 07, 2019	Johnson & Johnson Announces Submission of European Marketing Authorisation Applications for Janssen’s Investigational Ebola Vaccine Regimen